Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid LeukemiaRüdiger Hehlmann, Susanne Saußele, Nadine Pletsch et al.|Journal of Clinical Oncology|2011Cited by 323
Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IVRüdiger Hehlmann, Andreas Hochhaus, Martin C. Müller et al.|Journal of Clinical Oncology|2013Cited by 299
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IVSusanne Saußele, Michael Lauseker, Aloïs Gratwohl et al.|Blood|2009Cited by 220